ABSTRACT:
A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a vasodilating drug which works by blocking the degradative action of cGMP-specific phosphodiesterase type 5 (PDE5) on cyclic GMP in the smooth muscle cells lining the blood vessels supplying various tissues. These drugs dilate the corpora cavernosa of the penis, facilitating erection with sexual stimulation, and are used in the treatment of erectile dysfunction (ED). Sildenafil was the first effective oral treatment available for ED. Because PDE5 is also present in the smooth muscle of the walls of the arterioles within the lungs, two PDE5 inhibitors, sildenafil and tadalafil, are FDA-approved for the treatment of pulmonary hypertension. As of 2019, the wider cardiovascular benefits of PDE5 inhibitors are being appreciated.
Cite this article:
Mayur S. Jain, Shailesh K. Koradia. Phosphodiesterase-5 (PDE5) Inhibitors in the Treatment of Erectile Dysfunction: A Review. Asian Journal of Pharmaceutical Research. 2023; 13(1):63-7. doi: 10.52711/2231-5691.2023.00012
Cite(Electronic):
Mayur S. Jain, Shailesh K. Koradia. Phosphodiesterase-5 (PDE5) Inhibitors in the Treatment of Erectile Dysfunction: A Review. Asian Journal of Pharmaceutical Research. 2023; 13(1):63-7. doi: 10.52711/2231-5691.2023.00012 Available on: https://asianjpr.com/AbstractView.aspx?PID=2023-13-1-12
REFERENCES:
1. Tzoumas N, Farrah TE, Dhaun N, Webb DJ (November 2019). "Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease". British Journal of Pharmacology. 177 (24): 5467–5488. doi:10.1111/bph.14920. PMC 7707100. PMID 31721165.
2. Kandeel FR. "Treatment of Erectile Dsyfunction in Men with Heart Disease". Male Sexual Dysfunction: Pathophysiology and Treatment. CRC Press, 2013. p. 453.
3. Belch, Jill; Carlizza, Anita; Carpentier, Patrick H.; Constans, Joel; Khan, Faisel; Wautrecht, Jean-Claude; Visona, Adriana; Heiss, Christian; Brodeman, Marianne; Pécsvárady, Zsolt; Roztocil, Karel (2017-10-01). "ESVM guidelines – the diagnosis and management of Raynaud's phenomenon". Vasa. 46 (6): 413–423. doi:10.1024/0301-1526/a000661. ISSN 0301-1526. PMID 28895508.
4. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, et al. (November 2002). "Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats". Stroke. 33 (11): 2675–80. doi:10.1161/01.STR.0000034399.95249.59. PMID 12411660.
5. Webb DJ, Freestone S, Allen MJ, Muirhead GJ (March 1999). "Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist". The American Journal of Cardiology. 83 (5A): 21C–28C. doi:10.1016/S0002-9149(99)00044-2. PMID 10078539.
6. "FDA Announces Revisions to Labels for Cialis, Levitra and Viagra". Food and Drug Administration. 2007-10-18. Retrieved 2011-10-30.
7. Webb DJ, Freestone S, Allen MJ, Muirhead GJ (March 1999). "Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist". The American Journal of Cardiology. 83 (5A): 21C–28C. doi:10.1016/S0002-9149(99)00044-2. PMID 10078539.
8. FDA Announces Revisions to Labels for Cialis, Levitra and Viagra". Food and Drug Administration. 2007-10-18. Retrieved 2011-10-30.
9. Rao AR, Thwaini A, Ahmed HU, Shergill IS, Minhas S (July 2007). "The phosphodiesterase inhibitors and non-arteritic anterior ischaemic optic neuropathy: increased vigilance is necessary". BJU International. 100 (1): 3–4. doi:10.1111/j.1464-410X.2007.06839.x. PMID 17488310. S2CID 43862884.